Annie Dionne
A5001304246- Amyotrophic Lateral Sclerosis Research
- Neurogenetic and Muscular Disorders Research
- Parkinson's Disease Mechanisms and Treatments
- Peripheral Neuropathies and Disorders
- Myasthenia Gravis and Thymoma
- Dysphagia Assessment and Management
- Alzheimer's disease research and treatments
- Nerve Injury and Rehabilitation
- Antifungal resistance and susceptibility
- Neurological diseases and metabolism
- Vasculitis and related conditions
- Sarcoidosis and Beryllium Toxicity Research
- Ion channel regulation and function
- Cardiomyopathy and Myosin Studies
- Craniofacial Disorders and Treatments
- Phonetics and Phonology Research
- Multiple Sclerosis Research Studies
- Ocular Surface and Contact Lens
- Hereditary Neurological Disorders
- Cholinesterase and Neurodegenerative Diseases
- Ophthalmology and Visual Impairment Studies
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Parkinson's Disease and Spinal Disorders
- Cardiovascular Effects of Exercise
- RNA Research and Splicing
Université Laval
2009-2024
Centre hospitalier de l'Université Laval
2022
Université du Québec à Montréal
2022
Hôpital de l'Enfant-Jésus
2005-2021
Centre hospitalier universitaire de Québec
2016
Université de Sherbrooke
2000
Abstract Up to 16% of chronic inflammatory demyelinating polyneuropathy (CIDP) patients may present acutely. We performed a retrospective chart review on 30 acute (AIDP) and 15 acute‐onset CIDP (A‐CIDP) looking for any clinical or electrophysiological parameters that might differentiate AIDP from acutely presenting CIDP. A‐CIDP were significantly more likely have prominent sensory signs. They less autonomic nervous system involvement, facial weakness, preceding infectious illness, need...
Objective To evaluate safety, dose response, and preliminary efficacy of reldesemtiv over 12 weeks in patients with amyotrophic lateral sclerosis (ALS). Methods: Patients (≤2 years since diagnosis) slow upright vital capacity (SVC) ≥60% were randomized 1:1:1:1 to 150, 300, or 450 mg twice daily (bid) placebo; active treatment was 4-week follow-up. Primary endpoint change percent predicted SVC at weeks; secondary measures included ALS Functional Rating Scale-Revised (ALSFRS-R) muscle strength...
Objective: Amyotrophic lateral sclerosis (ALS) is a multi-system disorder characterized primarily by motor neuron degeneration, but may be accompanied cognitive dysfunction. Statistically appropriate criteria for establishing impairment (CI) in ALS are lacking. We evaluate quantile regression (QR), that accounts age and education, relative to traditional two standard deviation (SD) cutoff defining CI. Methods: QR of cross-sectional data from multi-center North American Control (NAC) cohort...
Abstract Although speech declines rapidly in some individuals with amyotrophic lateral sclerosis (ALS), longitudinal changes have rarely been characterized. The study objectives were to model the rate of decline speaking and intelligibility as a function disease onset site, sex, age at 166 ALS; estimate time loss from symptom onset. We also examined association between clinical (speaking rate/intelligibility) measures patient-reported ALS progression (ALSFRS-R). Speech declined faster...
In the Phase 3 MycarinG study (NCT03971422), six once-weekly subcutaneous infusions of rozanolixizumab significantly improved myasthenia gravis (MG)-specific outcomes versus placebo in patients with acetylcholine receptor or muscle-specific tyrosine kinase autoantibody-positive generalized MG (gMG). Following completion MycarinG, could enroll open-label extension MG0004 (NCT04124965) to receive chronic weekly rozanolixizumab. Patients were re-randomized 1:1 7 10 mg/kg for up 52 infusions....
Importance Treatment options for amyotrophic lateral sclerosis (ALS) remain suboptimal. Results from a phase 2 study of reldesemtiv in ALS suggested that it may slow disease progression. Objective To assess the effect vs placebo on functional outcomes ALS. Design, Setting, and Participants A Study to Evaluate Efficacy Safety Reldesemtiv Patients With Amyotrophic Lateral Sclerosis (COURAGE-ALS) was double-blind, placebo-controlled 3 randomized clinical trial conducted at 83 centers 16...
Abstract Background Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. Increasing age an important risk factor for developing ALS, thus the societal impact of this devastating disease will become more profound as population ages. A significant hurdle to finding effective treatment has been inability accurately quantify cerebral degeneration associated with ALS in humans. Advanced magnetic resonance imaging (MRI) techniques hold promise...
Amyotrophic lateral sclerosis (ALS) is a multisystem neurodegenerative disorder characterized by progressive degeneration of upper motor neurons and lower neurons, frontotemporal regions resulting in impaired bulbar, limb, cognitive function. Magnetic resonance imaging studies have reported cortical subcortical brain involvement the pathophysiology ALS. The present study investigates functional integrity resting-state networks (RSNs) their importance Intra- inter-network connectivity (Rs-FC)...
Abstract To determine the optimal recording site for phrenic nerve conduction studies, six different techniques were compared in 11 healthy volunteers (22 nerves). The mean diaphragm compound muscle action potential (CMAP) amplitude, side‐to‐side difference, and number of studies with a false‐positive result (CMAP amplitude <0.30 mV) each technique. largest (0.65 ± 0.23 mV, range 0.30–1.2 good right–left agreement (mean difference 0.15 no false positives was obtained using technique 1,...
Amyotrophic Lateral Sclerosis (ALS) is a complex neurodegenerative disorder characterized by motor neuron degeneration. Significant research has begun to establish brain magnetic resonance imaging (MRI) as potential biomarker diagnose and monitor the state of disease. Deep learning emerged prominent class machine algorithms in computer vision shown successful applications various medical image analysis tasks. However, deep methods applied neuroimaging have not achieved superior performance...
The corticospinal tract (CST) reveals progressive microstructural alterations in ALS measurable by DTI. aim of this study was to evaluate fractional anisotropy (FA) along the CST as a longitudinal marker disease progression ALS.
Objective: To understand current genetic testing practices at Canadian ALS clinics. Methods: An online survey and phone interviews, with clinicians practicing in 27 clinics Canada, were employed to collect data. Quantitative qualitative analyses conducted. Results: Ninety-three percent (25/27) of Canada are routinely ordering for familial ALS, while 33% (9/27) sporadic ALS. Barriers include a perceived lack an impact on treatment plan, difficulty obtaining approvals, primarily from...
Progressive cerebral degeneration in amyotrophic lateral sclerosis (ALS) remains poorly understood. Here, three-dimensional (3D) texture analysis was used to study longitudinal gray and white matter ALS from routine T1-weighted magnetic resonance imaging (MRI). Participants were included the Canadian Neuroimaging Consortium (CALSNIC) who underwent up three clinical assessments MRI at four-month intervals, 8 months after baseline (T0 ). Three-dimensional maps of feature autocorrelation...
The absence of disease modifying treatments for amyotrophic lateral sclerosis (ALS) is in large part a consequence its complexity and heterogeneity. Deep clinical biological phenotyping people living with ALS would assist the development effective target specific biomarkers to monitor progression inform on treatment efficacy. objective this paper present Comprehensive Analysis Platform To Understand Remedy Eliminate (CAPTURE ALS), an open translational platform scientific community currently...
Abstract We present a case of subacute weakness one hand with unusual sensory involvement including the upper thorax. Despite normal distal conduction studies, clinical diagnosis Lewis–Sumner syndrome was made and patient responded well to intravenous immunoglobulins. Repeated studies after exacerbation finally proved demyelinating nature neuropathy using proximal magnetic nerve stimulation. This underlies importance seeking blocks in patients suspected neuropathy. Muscle Nerve, 2006